| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f58e027d80c9f42687e27e11d4a8cc6a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2506-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-999
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2307
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2500-62 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0634
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate |
2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c13e0c3875bb1dc8145d09c52a8e3e01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1323b6293d7927414d9d97e69e2d9bbb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_09d47eddb7c2b77980817e2c772f61d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36fd056d31cbe6d34960790c5cdd10d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3811b4649dab525afedad9156c4eead |
| publicationDate |
2023-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2023016034-A1 |
| titleOfInvention |
ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS |
| abstract |
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022387488-A1 |
| priorityDate |
2019-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |